Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the patient navigator program
Publication date: Available online 26 March 2020Source: American Heart JournalAuthor(s): Carolyn M. Wu, Nancy M. Albert, Ty J. Gluckman, Di Lu, Susan Rogers, Julie Mobayed, Shilpa Patel, William S. Weintraub
Diabetes mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of hypoglycemic agents that have shown significant promise in the reduction of cardiovascular events. Current guideline recommendations do not support the use of these agents in patients with CKD stage 3 or higher. We performed a comprehensive meta-analysis to evaluate their cardiovascular effects in patients with type 2 DM and CKD stage 3 or higher. A comprehensive search was performed in PubMed, Cochrane central, and Embase. S...
Each year 790,000 people in the United States suffer from a myocardial infarction. This results in the permanent loss of cardiomyocytes and an irreversible loss of cardiac function. Current therapies lower mortality rates, but do not address the core pathology, which opens a pathway to step-wise heart failure. Utilizing stem cells to regenerate the dead tissue is a potential method to reverse these devastating effects. Several clinical trials have already demonstrated the safety of stem cell therapy. In this review, we highlight clinical trials, which have utilized various stem cell lineages, and discuss areas for future research.
ZOLL Medical, now a part of Asahi Kasei Group, won FDA approval for the latest version of its TherOx System. The product is designed to deliver SuperSaturated Oxygen (SSO2) therapy to limit heart muscle loss following “widowmaker” heart a...
Right heart failure (RHF) is a severe complication of myocardial infarction (MI). For critical patients in cardiogenic shock after MI temporary circulatory support (TCS) is necessary to provide sufficient cardiac output. The ProtekDuo ® dual-lumen cannula provides a minimally invasive option for TCS, with the TandemHeart® pump or a CentriMag™ assist device. Here, we present the first results with the ProtekDuo® cannula in the setting of acute MI with subsequent RHF as temporary right ventricular assist device (t-RVAD).
In conclusion, topographic and functional reorganization of the b3-AR/cGMP signalosome happens in heart failure and should be considered when designing new therapies acting via this receptor.
In conclusion, exercise improves cardiac function and glucose metabolism in HF mice through inhibiting HDAC4 and upregulating GLUT1 expression.
In conclusion, we reveal that targetingmir128-3p mitigates myocardial insulin resistance, thereafter slowing down the progression of heart failure post-ischemia.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly utilized in the setting of cardiogenic shock to provide hemodyamic and respiratory support to the acutely decompensating patient. Common scenarios include cardiogenic shock following acute myocardial infarction, acute exacerbation of chronic congestive heart failure, myocarditis, and postcardiotomy shock among others.1 This extremely aggressive therapy can be life-saving when appropriately applied, but inappropriate use can lead to unnecessary prolongation of patient and family suffering and significant costs and resource utilization.
Abstract Takotsubo syndrome (TTS), also known as stress cardiomyopathy, is a type of acute heart failure syndrome triggered by intense psychological or physiological stress. TTS typically manifests as acute chest pain, dyspnea or syncope that mimics an acute myocardial infarction but does not involve coronary artery obstruction. The current understanding of the pathogenesis of TTS suggests that sympathetic nervous system (SNS) activation plays a central role. Specifically, stress can activate the SNS and lead to the over-release of catecholamine, which have toxic effects on myocardial tissue when present at excess...
This article is protected by copyright. All rights reserved. PMID: 32222118 [PubMed - as supplied by publisher]